证券代码：300558 证券简称：贝达药业 公告编号：2025-063 贝达药业股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 贝达药业股份有限公司（以下简称"公司"）第四届董事会第二十六次会议 决定于 2025 年 9 月 26 日（星期五）14:30 召开 2025 年第一次临时股东大会（以 下简称"本次股东大会"），现将本次股东大会的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2025 年第一次临时股东大会 2、股东大会的召集人：本次股东大会经公司第四届董事会第二十六次会议决 议召开，由公司董事会召集举行。 3、会议召开的合法、合规性：公司第四届董事会第二十六次会议审议通过 《关于召开公司 2025 年第一次临时股东大会的议案》，本次股东大会的召开符 合有关法律法规、深圳证券交易所业务规则和《贝达药业股份有限公司章程》等 的规定。 4、会议召开日期和时间 现场会议召开日期、时间：2025 年 9 月 26 日（星期五）14:30 网络投票时间：2025 年 9 月 26 日 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-059 贝达药业股份有限公司 第四届监事会第二十三次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席张洋南先生召集，会议通知于 2025 年 9 月 4 日 以电子邮件、电话等形式送达全体监事，监事会会议通知中包括会议的相关材料， 同时列明了会议的召开时间、地点、内容和方式。 2、本次监事会于 2025 年 9 月 10 日在公司杭州总部 3 楼会议室召开，采取现 场会议和电话会议相结合的方式，现场投票表决。 3、本次监事会应到 3 人，实际出席会议人数为 3 人。 4、本次监事会由监事会主席张洋南先生主持，公司证券事务代表沈剑豪先 生列席了本次会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《贝达药业股份有限公司章程》（以下简称"《公司章程》"）的有关 规定。 二、监事会会议审议情况 1、会议审议并通过了《关于公司发行 H 股股票并在香港联合交易所有限公 司主板上市的议案》 为进一步推进公司国际化 ...

证券代码：300558 证券简称：贝达药业 公告编号：2025-058 贝达药业股份有限公司 第四届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、本次董事会由董事长丁列明先生召集，会议通知于 2025 年 9 月 4 日以电 话、邮件等形式送达全体董事，董事会会议通知中包括会议的相关材料，同时列 明了会议的召开时间、地点、内容和方式。 2、本次董事会于 2025 年 9 月 10 日在公司杭州总部行政大楼十五楼会议室召 开，采取现场会议和电话会议结合的方式现场投票表决。 3、本次董事会应到 12 人，实际出席会议人数 12 人。 4、本次董事会由董事长丁列明先生主持，公司董事会秘书吴灵犀先生列席 了本次会议。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《贝达药业股份有限公司章程》（以下简称"《公司章程》"）的有关 规定。 二、董事会会议审议情况 1、会议审议并通过了《关于公司发行 H 股股票并在香港联合交易所有限公 司主板上市的议案》 为进一步推进公司国际化进程，提升 ...

贝达药业(300558.SZ)公告称，为提升资本实力和综合竞争力，深入推进国际化进程，公司拟发行境外 上市股份（H股）并申请在香港联交所主板挂牌上市。公司将充分考虑现有股东利益和境内外资本市场 情况，在股东大会决议有效期内选择适当时机和发行窗口完成本次发行上市。目前，公司正与相关中介 机构就本次发行上市的相关工作进行商讨，具体细节尚未最终确定。本次发行上市尚需提交公司股东大 会审议，并需取得中国证监会和香港联交所等相关政府机关、监管机构、证券交易所备案、批准和/或 核准。 ...

Investment Rating - The report maintains a "Market Weight" rating for the pharmaceutical and biotechnology industry [6][29]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 1.27% from August 22 to September 4, 2025, which is approximately 3.07 percentage points lower than the index [13][29]. - Most sub-sectors within the industry recorded negative returns during the same period, with the medical research outsourcing and chemical preparation sectors showing the highest gains of 12.17% and 5.45%, respectively. In contrast, the in vitro diagnostics and raw materials sectors experienced declines of 5.96% and 4.95% [16][19]. - Approximately 22% of stocks in the industry recorded positive returns, while around 78% experienced negative returns during the reporting period [17][19]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 55.41 times, with a relative PE ratio of 4.23 times compared to the CSI 300 index, indicating little change in industry valuation [20][29]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 1.27% from August 22 to September 4, 2025 [13]. - Most sub-sectors recorded negative returns, with medical research outsourcing and chemical preparations leading in gains [16]. - About 22% of stocks in the industry had positive returns, while 78% had negative returns [17]. 2. Industry News - The National Healthcare Security Administration announced the list of drugs for the 2025 National Basic Medical Insurance, with 718 submissions and 535 passing the initial review [27]. - The report highlights the upcoming national medical insurance negotiations and the analysis of 25 traditional Chinese medicine products [27]. 3. Company Announcements - Guangzhou Baiyunshan Pharmaceutical Group announced that its subsidiary received approval for a drug to pass the consistency evaluation for generic drugs [28]. 4. Industry Outlook - The report suggests focusing on investment opportunities in the innovative drug sector and related areas, including medical devices and traditional Chinese medicine [29][32].

Investment Rating - The report has downgraded the investment rating for the pharmaceutical and biotechnology industry, indicating that most sub-sectors are under performance pressure and suggesting a focus on performance improvement directions [1]. Core Insights - The overall revenue and net profit attributable to the parent company in the pharmaceutical and biotechnology industry saw a decline in H1 2025, with total revenue of 1.23 trillion yuan, down 2.7% year-on-year, and net profit of 99.15 billion yuan, down 3.9% year-on-year [4][13]. - Most sub-sectors experienced a year-on-year decline in performance in H1 2025, with only a few segments like medical R&D outsourcing and other biological products showing positive growth [4][14]. - The investment strategy suggests focusing on innovative drugs and medical devices, highlighting companies such as Heng Rui Medicine, Bei Da Pharmaceutical, and Mindray Medical as potential investment opportunities [4]. Summary by Sections Overall Industry Performance - In H1 2025, the pharmaceutical and biotechnology industry reported total revenue of 1.23 trillion yuan, a decrease of 2.7% year-on-year, and a net profit of 99.15 billion yuan, down 3.9% year-on-year [4][13]. - The industry also saw a decline in non-recurring net profit, which fell by 13.2% year-on-year to 82.67 billion yuan [4]. Sub-sector Performance - **Chemical Preparations**: Revenue decreased by 3.2% to 271.41 billion yuan, and net profit fell by 7.5% to 25.72 billion yuan in H1 2025 [23][30]. - **Traditional Chinese Medicine**: Revenue dropped by 5.5% to 178.60 billion yuan, with net profit slightly down by 0.1% to 22.34 billion yuan [32][37]. - **Biological Products**: Revenue fell by 17.6% to 55.80 billion yuan, and net profit decreased by 31.3% to 6.36 billion yuan [40][45]. - **Pharmaceutical Commerce**: Revenue was 514.18 billion yuan, a slight decline of 0.2%, while net profit increased by 7.2% to 12.04 billion yuan [49][52]. Investment Strategy - The report recommends focusing on innovative drugs and medical devices, with specific companies highlighted for potential investment, including Heng Rui Medicine, Bei Da Pharmaceutical, and Mindray Medical [4].

Group 1 - On September 3, Benda Pharmaceutical experienced a slight decline of 0.01% with a trading volume of 856 million yuan [1] - The financing data for Benda Pharmaceutical on that day showed a financing purchase amount of 81.21 million yuan and a financing repayment of 109 million yuan, resulting in a net financing outflow of 28 million yuan [1] - As of September 3, the total balance of margin trading for Benda Pharmaceutical was 590 million yuan, with a financing balance of 578 million yuan, accounting for 1.83% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, the number of shareholders for Benda Pharmaceutical reached 32,100, an increase of 9.97% from the previous period, while the average circulating shares per person decreased by 9.08% to 13,064 shares [2] - For the first half of 2025, Benda Pharmaceutical reported a revenue of 1.731 billion yuan, representing a year-on-year growth of 15.37%, while the net profit attributable to the parent company was 140 million yuan, a decrease of 37.53% year-on-year [2] - Since its A-share listing, Benda Pharmaceutical has distributed a total of 669 million yuan in dividends, with 184 million yuan distributed over the past three years [2]

Core Viewpoint - Beida Pharmaceutical emphasizes that its revenue is primarily driven by the number of patients covered by its products, aligning product shipment with terminal demand [2] Group 1 - The company confirms revenue upon the transfer of product control to customers, indicating a direct correlation between product availability and revenue recognition [2] - Beida Pharmaceutical has maintained a stable revenue growth by implementing an academic-driven promotion strategy, focusing on the differentiated therapeutic advantages of its products [2] - The efficacy and safety of the company's products have gained recognition from both doctors and patients, contributing to consistent revenue performance [2]

Core Viewpoint - The company emphasizes its commitment to innovation and has successfully launched 8 new drugs while developing a promising pipeline with over 20 projects focused on various cancers and eye diseases [2] Company Summary - The company is concentrating resources on developing new drugs for high-incidence cancers such as lung and breast cancer [2] - The company has established a strong research and development pipeline, with ongoing projects targeting diseases like lung cancer, breast cancer, and wet age-related macular degeneration (wAMD) [2] - The company recognizes the advantages of small molecule drugs in terms of oral activity, permeability, stability, and production costs, and is exploring how to integrate these advantages with other therapeutic modalities like antibodies [2]

Core Viewpoint - Betta Pharmaceuticals has demonstrated the differentiated clinical efficacy of its drug, Beifuqun, with favorable progression-free survival (PFS) data and controllable safety profile, indicating potential for effective market promotion and patient benefit [1] Group 1: Clinical Research and Product Development - Clinical research results indicate that Beifuqun shows good performance in PFS data, highlighting its differentiated clinical treatment capability [1] - The overall adverse event safety profile of Beifuqun is manageable, suggesting a strong safety record [1] - The company plans to leverage the data advantages of Beifuqun to develop effective promotional strategies [1] Group 2: Commercialization and Revenue Growth - The company aims to achieve comprehensive market coverage quickly, benefiting more patients through its successful commercialization experience with already launched products [1] - The collaboration with Yifang is ongoing, with both parties communicating to resolve new developments in their commercial partnership [1] - The company has established a robust revenue growth and cash flow through a virtuous cycle of "R&D - commercialization - reinvestment," ensuring orderly advancement of its R&D pipeline [1] Group 3: Future Prospects - Recent interim data from the postoperative adjuvant clinical trial of Ensatinib has reached the study endpoint, marking a significant achievement in resource concentration and development focus [1] - This achievement is expected to have a positive impact on the company's future revenue [1]